23 search results for: disease modification

Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD and Dr. Peter Lio, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies. Moreover, explores the potential opportunities for early intervention to alter disease trajectories and the possibilities for disease modification in atopic dermatitis.

Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.

Dr. Yu and Dr. Wine Lee discuss the clinical presentation and burden of atopic dermatitis, the role of type 2 inflammation in the development of atopic comorbidities, and the importance of early intervention in potentially preventing cumulative life course impairment in AD at PeDRA 2025.

Experience this engaging presentation by Dr. Donna Culton, Prof. Dédée Murrell, and Prof. Ulrike Raap, who highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

In this exclusive video interview, Dr Paula Luna discusses how disease modification can be defined in AD and how IgE may be used as a biomarker in AD.

Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.